Forian Inc. has entered into a definitive merger agreement to be acquired by a consortium of investors led by Chairman and Chief Executive Officer Max Wygod, together with certain other senior executives and existing stockholders. The all-cash transaction values the company's equity at approximately $68 million and will return Forian to private ownership. This shift from public to private status carries significant implications for the company's strategic direction and operational flexibility, removing the pressures of quarterly earnings reports and potentially allowing for longer-term investments in its core data capabilities.
Under the agreement, Forian stockholders will receive $2.17 per share in cash, representing a premium of approximately 22.6% to the company's unaffected closing price as of August 22, 2025. The transaction was unanimously approved by the Forian Board of Directors, acting upon the unanimous recommendation of a Special Committee of disinterested and independent directors formed in response to the consortium's initial proposal. This premium and the board's endorsement highlight the transaction's perceived fairness and value to shareholders, which is crucial in such management-led buyouts to ensure investor interests are protected.
The transaction is expected to close in the second quarter of 2026, subject to the satisfaction of the minimum tender condition and other closing conditions. Following completion, Forian will no longer be listed on the Nasdaq Stock Market or any public exchange. The company will continue to be led by Max Wygod and the current leadership team, maintaining its headquarters in Newtown, Pennsylvania and operating under the Forian name. This continuity in leadership suggests the acquisition is aimed at strategic realignment rather than operational overhaul, allowing the existing team to execute its vision without public market scrutiny.
Forian provides data management capabilities and proprietary information and analytics solutions for customers in life sciences, healthcare, and financial services. The company has industry leading expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. More information about the company is available at https://www.forian.com. This focus on healthcare data is increasingly critical as industries seek to leverage big data for insights, making Forian's private ownership potentially advantageous for investing in technology and data assets away from public investor expectations.
Concurrent with entering into the merger agreement, consortium members have committed to provide the funding necessary to pay the cash consideration, and the transaction is not subject to a financing condition. The Forian Board of Directors unanimously recommends that all stockholders tender their shares into the offer. Important documents related to the transaction will be filed with the SEC and available at https://www.sec.gov. Investors may also obtain these documents under the "Investors" section of the company's website. The solicitation and offer to purchase shares will only be made pursuant to formal tender offer materials that will be filed with regulatory authorities. This structure ensures transparency and regulatory compliance, which is essential for maintaining trust in such significant corporate transitions.
